We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

162 hedge funds and large institutions have $3.22B invested in China Biologic Products Holdings, Inc. in 2016 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 60 increasing their positions, 44 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 18

55% more capital invested

Capital invested by funds: $2.08B → $3.22B (+$1.15B)

36% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 44

17% more funds holding

Funds holding: 138162 (+24)

14% more funds holding in top 10

Funds holding in top 10: 78 (+1)

24% less call options, than puts

Call options by funds: $18.3M | Put options by funds: $24.1M

Holders
162
Holders Change
+24
Holders Change %
+17.39%
% of All Funds
4.32%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.21%
New
42
Increased
60
Reduced
44
Closed
18
Calls
$18.3M
Puts
$24.1M
Net Calls
-$5.85M
Net Calls Change
-$5.14M
Name Holding Trade Value Shares
Change
Change in
Stake
ROTUOC
101
Regents of the University of California
California
$1.57M +$1.49M +12,600 New
State Street
102
State Street
Massachusetts
$1.5M +$156K +1,324 +12%
HLA
103
Hamilton Lane Advisors
Pennsylvania
$1.42M +$1.35M +11,433 New
Geode Capital Management
104
Geode Capital Management
Massachusetts
$1.35M +$8.14K +69 +0.6%
Nordea Investment Management
105
Nordea Investment Management
Sweden
$1.27M +$45.2K +383 +4%
JCP
106
Jabre Capital Partners
Switzerland
$1.25M +$1.18M +10,000 New
Bank of Montreal
107
Bank of Montreal
Ontario, Canada
$1.2M +$1.14M +9,626 New
TC
108
TFS Capital
Pennsylvania
$1.18M +$1.12M +9,494 New
Lazard Asset Management
109
Lazard Asset Management
New York
$1.08M +$106K +900 +12%
First Trust Advisors
110
First Trust Advisors
Illinois
$1.08M -$148K -1,253 -13%
PAS
111
Point72 Asia (Singapore)
Singapore
$996K +$944K +8,000 New
D.E. Shaw & Co
112
D.E. Shaw & Co
New York
$913K -$529K -4,477 -38%
QI
113
Quotient Investors
New York
$909K -$201K -1,700 -19%
Northern Trust
114
Northern Trust
Illinois
$872K
SO
115
STRS Ohio
Ohio
$861K +$850K +7,200 New
MCM
116
McKinley Capital Management
Alaska
$799K +$59K +500 +8%
SG Americas Securities
117
SG Americas Securities
New York
$747K +$708K +5,998 New
Citigroup
118
Citigroup
New York
$742K +$32.2K +273 +5%
MIP
119
Marietta Investment Partners
Wisconsin
$735K
Capital Fund Management (CFM)
120
Capital Fund Management (CFM)
France
$710K +$375K +3,179 +126%
RFC
121
Regions Financial Corp
Alabama
$692K +$657K +5,565 New
BIM
122
BlackRock Investment Management
Delaware
$685K +$474K +4,015 +270%
VKH
123
Virtu KCG Holdings
New York
$658K +$624K +5,287 New
SEI Investments
124
SEI Investments
Pennsylvania
$632K +$83.8K +710 +16%
ST
125
Spot Trading
Illinois
$610K -$153K -1,300 -21%

CBPO Hedge Fund Activity: Q3 2016 in Review

162 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q3 2016, worth a combined $3.22B — up 55% from $2.08B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new CBPO positions and 18 closed out — a net gain of 24 holders — while 60 added to existing stakes and 44 trimmed.

The largest buyer was Fidelity International, adding an estimated $51.4M. The largest seller was Warburg Pincus, cutting an estimated $154M.

  • 162 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q3 2016, up from 138 in Q2 2016.
  • Funds reported $3.22B of China Biologic Products Holdings, Inc. stock for Q3 2016, up 55% quarter-over-quarter.
  • 42 funds opened new China Biologic Products Holdings, Inc. positions in Q3 2016 and 18 closed out, a net change of +24 holders.
  • The largest China Biologic Products Holdings, Inc. buyer in Q3 2016 was Fidelity International, an estimated $51.4M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q3 2016 was Warburg Pincus, an estimated $154M sold.

Based on aggregated 13F filings for Q3 2016.